Institutul Regional De Oncologie Iasi

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• Follicular lymphoma1 trial
• Head and neck cancer1 trial
• Multiple myeloma1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Completed2 trials

Lead sponsor

• Glaxosmithkline Research & Development Limited2 trials
• Amgen1 trial
• Amgen Inc.1 trial
• BeOne Medicines1 trial
• Bristol-Myers Squibb1 trial
• and 2 more

Running trials

• Recruiting

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· Phase 3· BeOne Medicines· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source